Protagonist Therapeutics, Inc. (PTGX)
136.24
+0.34
(+0.25%)
USD |
NASDAQ |
Nov 10, 16:00
136.24
0.00 (0.00%)
After-Hours: 17:35
Protagonist Therapeutics Price to Book Value : 8.190 for Nov. 10, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 09, 2026 | 8.169 |
| November 06, 2026 | 7.937 |
| November 05, 2026 | 8.131 |
| November 04, 2026 | 8.618 |
| November 03, 2026 | 8.43 |
| November 02, 2026 | 8.378 |
| October 30, 2026 | 8.707 |
| October 29, 2026 | 8.676 |
| October 28, 2026 | 8.544 |
| October 27, 2026 | 8.483 |
| October 26, 2026 | 8.435 |
| October 23, 2026 | 8.321 |
| October 22, 2026 | 8.387 |
| October 21, 2026 | 8.300 |
| October 20, 2026 | 8.295 |
| October 19, 2026 | 8.081 |
| October 16, 2026 | 7.739 |
| October 15, 2026 | 8.208 |
| October 14, 2026 | 8.192 |
| October 13, 2026 | 8.325 |
| October 12, 2026 | 8.709 |
| October 09, 2026 | 8.640 |
| October 08, 2026 | 8.410 |
| October 07, 2026 | 8.471 |
| October 06, 2026 | 8.337 |
| Date | Value |
|---|---|
| October 05, 2026 | 8.454 |
| October 02, 2026 | 8.419 |
| October 01, 2026 | 8.367 |
| September 30, 2026 | 8.469 |
| September 29, 2026 | 10.83 |
| September 28, 2026 | 10.95 |
| September 25, 2026 | 10.90 |
| September 24, 2026 | 10.55 |
| September 23, 2026 | 10.66 |
| September 22, 2026 | 11.15 |
| September 21, 2026 | 11.14 |
| September 18, 2026 | 10.99 |
| September 17, 2026 | 11.04 |
| September 16, 2026 | 10.98 |
| September 15, 2026 | 11.02 |
| September 14, 2026 | 11.36 |
| September 11, 2026 | 11.39 |
| September 10, 2026 | 11.16 |
| September 09, 2026 | 11.15 |
| September 08, 2026 | 11.22 |
| September 04, 2026 | 11.20 |
| September 03, 2026 | 11.44 |
| September 02, 2026 | 11.23 |
| September 01, 2026 | 11.26 |
| August 31, 2026 | 11.35 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Johnson & Johnson | 8.288 |
| AbbVie, Inc. | -- |
| BioMarin Pharmaceutical, Inc. | 1.769 |
| Gilead Sciences, Inc. | 16.27 |
| Nektar Therapeutics | 1.429 |
Price to Book Value Related Metrics
| PE Ratio | 28.86 |
| PS Ratio | 17.12 |
| PEG Ratio | 0.0447 |
| Price to Free Cash Flow | 86.52 |
| Price | 136.24 |
| Earnings Yield | 3.47% |
| Market Cap | 8.885B |
| PEGY Ratio | 0.0447 |
| Operating PE Ratio | 29.23 |
| Normalized PE Ratio | 28.86 |